Key points are not available for this paper at this time.
Background: (176 targets) performance of a faecal mNGS assay on clinically relevant bacterial, eukaryotic, viral, virulence factor (VF) and antimicrobial resistance (AMR) genes. Methods: faecal samples containing targets reflecting the limit of detection of the assay were used to evaluate performance across all 176 targets. Results: benchmarking showed strong performance for all 176 targets down to analytically defined detection limits. Conclusions: The faecal mNGS assay performed competitively with existing diagnostic techniques while substantially expanding actionable detection in a single assay. These results support stool mNGS as a high-yield second-line or syndromic test for gastrointestinal infection, enabling improved recognition of rare pathogens, co-infections, and resistance determinants.
Parks et al. (Mon,) studied this question.